Long noncoding RNAs (lncRNAs) are involved in diabetogenesis in experimental models, yet their role in humans is unclear. The paper investigates whether circulating lncRNAs associate with incident type 2 diabetes in older adults.

Read full article (Diabetes Care 2023;46(6):1239–1244)

Artificial intelligence (AI) is becoming increasingly important in cardiovascular medicine - but how does AI learn? Thomas F. Lüscher and Florian A. Wenzl provide their perspective in the European Heart Journal. 

The Global Registry of Acute Coronary Events (GRACE) risk score, a guideline-recommended risk stratification tool for patients presenting with acute coronary syndromes (ACS), does not consider the extent of myocardial injury.

Read full article (JAMA Cardiology, August 2023)

Circulating dipeptidyl peptidase 3 (cDPP3) is a protease involved in the degradation of angiotensin II which disturbs peripheral blood pressure regulation and compromises left ventricular function. A new study by Florian A. Wenzl et al. published in the European Heart Journal identified cDPP3 as a novel marker of cardiogenic shock (CS) and increased mortality in patients with (ACS).

Circulating levels of acetylcarnitine independently predict residual cardiovascular risk in patients with ACS.

Read full article (European Heart Journal, 41, 2, 2020)

New Frontiers in Cardiovascular Medicine E-book on the Implications of lipids and modified lipoproteins in atherogenesis: From mechanisms towards novel diagnostic and therapeutic targets. Check it out here!

Enhancing SIRT1 activity exerts beneficial cardiovascular effects. In diabetes, plasma SIRT1 levels are reduced.

Read full article (Cardiovascular Research (2023) 00, 1–12)

In collaboration with the Medical University of Vienna and the University Hospital of Zurich, members of the Center for Molecular Cardiology have studied the role of growth differentiation factor-15 (GDF-15) for its predictive utility for adverse events in patients with cancer.

Access the full article

Low-density lipoprotein (LDL)-cholesterol (LDL-C) promotes atherosclerotic cardiovascular disease (ASCVD), with changes in LDL electronegativity modulating its pro-atherogenic/pro-thrombotic effects.

Read full article (Atherosclerosis 376 (2023) 43–52)

Identifying the IRA in patients with ACSs has profound diagnostic, therapeutic, and prognostic implications

Read full article (Eur Heart J Qual Care Clin Outcomes (2023) 0, 1–11)